InflaRx (NASDAQ:IFRX) Short Interest Up 46.2% in February

InflaRx (NASDAQ:IFRX) was the target of a large increase in short interest in the month of February. As of February 28th, there was short interest totalling 564,700 shares, an increase of 46.2% from the February 13th total of 386,300 shares. Based on an average daily trading volume, of 382,600 shares, the days-to-cover ratio is currently 1.5 days. Currently, 1.0% of the company’s stock are short sold.

Analyst Ratings Changes

Separately, HC Wainwright reissued a “buy” rating and issued a $8.00 price objective on shares of InflaRx in a research note on Friday, March 7th.

Institutional Inflows and Outflows

Large investors have recently modified their holdings of the stock. Raymond James Financial Inc. purchased a new stake in InflaRx in the 4th quarter valued at $1,576,000. Commonwealth Equity Services LLC grew its stake in shares of InflaRx by 20.5% in the 4th quarter. Commonwealth Equity Services LLC now owns 111,500 shares of the company’s stock worth $275,000 after acquiring an additional 19,000 shares in the last quarter. Geode Capital Management LLC raised its holdings in shares of InflaRx by 32.8% in the fourth quarter. Geode Capital Management LLC now owns 48,136 shares of the company’s stock valued at $119,000 after purchasing an additional 11,900 shares during the last quarter. Walleye Capital LLC bought a new position in shares of InflaRx during the fourth quarter valued at about $51,000. Finally, Two Sigma Securities LLC purchased a new position in InflaRx during the fourth quarter worth about $28,000. Institutional investors own 42.39% of the company’s stock.

InflaRx Stock Performance

Shares of NASDAQ IFRX opened at $1.22 on Tuesday. The firm’s 50-day simple moving average is $2.03 and its 200 day simple moving average is $1.91. The stock has a market cap of $81.90 million, a price-to-earnings ratio of -1.13 and a beta of 1.98. InflaRx has a fifty-two week low of $1.13 and a fifty-two week high of $2.82.

About InflaRx

InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology in Germany and the United States. The company's C5a is an inflammatory mediator that is involved in the progression of a variety of autoimmune and other inflammatory diseases. Its lead product candidate is vilobelimab, a novel intravenously delivered first-in-class anti-C5a monoclonal antibody, which completed the Phase III clinical trial for the treatment of hidradenitis suppurativa, a rare and chronic debilitating systemic inflammatory skin disease; for the treatment of anti-neutrophil cytoplasm antibody associated vasculitis, a rare and life-threatening autoimmune disease that is in Phase II trial; to treat pyoderma gangraenosum, a chronic inflammatory skin disorder that is in Phase IIa exploratory study; and for the treatment of PD-1/PD-L1 inhibitor resistant/refractory locally advanced or metastatic cutaneous squamous cell carcinoma that is in Phase II clinical development stage.